I. V. Annexe, Application SMAC (SIR-Spheres ® Microspheres Activity Calculator) fournie par SIRTeX pour calculer l'activité nécessaire de SIR-Spheres ®

V. Annexe, Exemple du calcul de dose absorbée avec les microsphères marquées à l'yttrium-90 en résine selon le modèle par partition

V. I. Annexe, Algorithme de calcul d'activité en SIRT recommandé par Lau et al (111) pour un traitement réalisé à l'aide de microsphères en résine

R. Zimmermann, La Médecine nucléaire (La radioactivité au service du diagnostic et de la thérapie), 2006.

G. Galy and M. Fraysse, Radiopharmacie et médicaments radiopharmaceutiques, 2012.

D. Blanc and G. Portal, Précis de physique nucléaire, 2004.

. Pouget-jean-pierre, Radiobiologie et radiopathologie appliquées à la médecine nucléaire, 2018.

, Directive 89/343/CEE du conseil du 3 mai 1989 prévoyant des dispositions complémentaires pour les produits radiopharmaceutiques

, Loi no 92-1279 du 8 décembre, 1992.

, Bonnes pratiques de préparations. JORF. 21 décembre, 2007.

, Arrêté du 26 mars 1974 relatif à la compétence des personnes pouvant être autorisées à utiliser des radioéléments en sources non scellées à des fins médicales

, Arrêté du 15 octobre 1992 modifiant l'arrêté du 26 mars 1974 relatif à la compétence des personnes pouvant être autorisées à utiliser des radioéléments en sources non scellées à des fins médicales

, Décret no 2000-1316 du 26 décembre 2000 relatif aux pharmacies à usage intérieur et modifiant le Code de la santé publique

, Arrêté du 1er décembre 2003 relatif aux qualifications et à la formation des pharmaciens utilisant des médicaments radiopharmaceutiques dans les établissements de santé et les syndicats inter-hospitaliers. JORF no 25 du 30 janvier, 2004.

, Analyse des données relatives à la mise à jour des niveaux de référence diagnostiques en radiologie et en médecine nucléaire, 2013.

V. Valoso-jéronimo, C. Pestean, and P. Hogg, Radionuclide metabolic therapy clinical aspects, dosimetry and imaging: a technologist's guide

J. I. Raoul, J. F. Bretagne, J. P. Caucanas, E. A. Pariente, J. Boyer et al., Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol, Cancer. 15 janv, vol.69, issue.2, pp.346-52, 1992.

R. Loeevinger and M. Berman, A schema for absorbed-dose calculations for biologicallydistributed radionuclides, J Nucl Med Off Publ Soc Nucl Med. févr, vol.1, pp.9-14, 1968.

R. Salem and K. G. Thurston, Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies, J Vasc Interv Radiol. août, vol.17, issue.8, pp.1251-78, 2006.

S. Favelier, T. Germain, P. Genson, J. Cercueil, D. A. Krausé et al., Anatomy of liver arteries for interventional radiology, Diagn Interv Imaging. juin, vol.96, issue.6, pp.537-583, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02279658

M. L. Schmidt, Anatomie du foie : ce qu'il faut savoir, 2007.

P. Kamina, A. L'essentiel-en, and . Maloine,

. Btg-interventional-medecine, Microsphères de verre d'yttrium-90 TheraSphere® -Mode d'emploi, 2016.

. Sirtex, Microsphères SIR-Spheres -Programme de formation -Médecins et établissements hospitaliers, 2016.

. Ansm.-l'ansm, évaluation, d'expertise et de décision -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2018.

R. G. Selwyn, R. J. Nickles, B. R. Thomadsen, L. A. Dewerd, and J. A. Micka, A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr, Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. mars, vol.65, issue.3, pp.318-345, 2007.

Y. Kao, J. D. Steinberg, Y. Tay, G. K. Lim, J. Yan et al., Post-radioembolization yttrium-90 PET/CT -part 1: diagnostic reporting, EJNMMI Res. 25 juill, vol.3, issue.1, p.56, 2013.

K. Eckerman and A. Endo, ICRP Publication 107. Nuclear decay data for dosimetric calculations, Ann ICRP, vol.38, issue.3, pp.7-96, 2008.

. Sirtex, Microsphères SIR-Spheres -Programme de formation -Médecins et établissements hospitaliers, 2016.

. Bérnardini-michela, Présentation de l'IRSN -SIRT : Radiothérapie Interne Sélective -Radioprotection des patients, Juin, 2014.

. Garin-e, Radioembolisation des tumeurs hépatiques -10 ème Colloque Francophone d'Oncologie Digestive, vol.9, 2013.

J. C. Andrews, S. C. Walker, R. J. Ackermann, L. A. Cotton, W. D. Ensminger et al., Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up, J Nucl Med Off Publ Soc Nucl Med, vol.35, issue.10, pp.1637-1681, 1994.

. Fontaine-pierre-antoine, Présentation Congrès SNRPH Tours -Evaluation de l'élimination urinaire de l'Yttrium-90 après administration de TheraSphere et de SIR-Spheres, 2011.

S. Walrand, M. Hesse, C. Chiesa, R. Lhommel, and J. F. , The Low Hepatic Toxicity per Gray of 90Y Glass Microspheres Is Linked to Their Transport in the Arterial Tree Favoring a Nonuniform Trapping as Observed in Posttherapy PET Imaging, J Nucl Med. 1 janv, vol.55, issue.1, pp.135-175, 2014.

R. J. Lewandowski, J. Minocha, K. Memon, A. Riaz, V. L. Gates et al., Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort, Eur J Nucl Med Mol Imaging. mars, vol.41, issue.3, pp.486-93, 2014.

. Sirtex, SIR-Spheres Microspheres -Package Insert, 2016.

S. Laffont, V. Ardisson, and E. Garin, Radioprotection du personnel lors des traitements par Microsphères Y90. 28 mai, 2014.

D. Azria, G. P. Trédaniel, and J. Cancérologie, Collège national des enseignants en cancérologie (France), 2017.

K. Memon, R. J. Lewandowski, L. Kulik, A. Riaz, M. F. Mulcahy et al., Radioembolization for Primary and Metastatic Liver Cancer, Semin Radiat Oncol, vol.21, issue.4, pp.294-302, 2011.

A. Braat, M. Smits, M. Braat, A. F. Van-den-hoven, J. F. Prince et al., 90Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments, J Nucl Med. 1 juill, vol.56, issue.7, pp.1079-87, 2015.

V. Vilgrain, H. Pereira, E. Assenat, B. Guiu, A. D. Ilonca et al., Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an openlabel randomised controlled phase 3 trial, Lancet Oncol. déc, vol.18, issue.12, pp.1624-1660, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01727346

G. A. Van-hazel, V. Heinemann, N. K. Sharma, M. Findlay, J. Ricke et al., Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, issue.15, pp.1723-1754, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01282335

K. A. Mcglynn and W. T. London, The Global Epidemiology of Hepatocellular Carcinoma: Present and Future, Clin Liver Dis. mai, vol.15, issue.2, pp.223-266, 2011.

N. Dilou, B. Patouillard, and J. Audigier,

, Gastroenterol Clin Biol. avr, vol.28, issue.4, pp.359-66, 2004.

C. Shuqun, W. Mengchao, C. Han, S. Feng, Y. Jiahe et al., Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein, Hepatogastroenterology. mars, vol.54, issue.74, pp.499-502, 2007.

S. Ju-xian, S. Jie, L. Nan, G. Wei-xing, W. Meng-chao et al., Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma, Cancer Biol Med, vol.13, issue.4, p.452, 2016.

J. Shi, E. Lai, N. Li, W. Guo, J. Xue et al., A new classification for hepatocellular carcinoma with portal vein tumor thrombus, J Hepato-Biliary-Pancreat Sci. janv, vol.18, issue.1, pp.74-80, 2011.

, EASL-EORTC Clinical practical guidelines: Management of Hepatocellular Carcinoma, European Association for the Study of the Liver (EASL), vol.56, pp.908-943, 2012.

, The Cancer of the Liver Italian Program (Clip) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients, Hepatology. sept, vol.28, issue.3, pp.751-756, 1998.

L. S. Fournier, S. Ammari, R. Thiam, and C. Cuénod, Critères de la réponse tumorale en imagerie : RECIST, mRECIST, Cheson, J Radiol Diagn Interv. juill, vol.95, issue.7-8, pp.678-92, 2014.

I. Ruiz and C. Féray, Prise en charge du carcinome hépatocellulaire. Cancer/Radiothérapie, oct, vol.19, issue.6-7, pp.410-415, 2015.

F. , Thésaurus National de Cancérologie Digestive -Carcinome hépatocellulaire, 2017.

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, N Engl J Med. 24 juill, vol.359, issue.4, pp.378-90, 2008.

P. Hilgard, M. Hamami, A. E. Fouly, A. Scherag, S. Müller et al., Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, vol.52, issue.5, pp.1741-1750, 2010.

B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini et al., Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatol Baltim Md. 2 sept, vol.54, issue.3, pp.868-78, 2011.

R. Salem, R. J. Lewandowski, M. F. Mulcahy, A. Riaz, R. K. Ryu et al., Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology. janv, vol.138, issue.1, pp.52-64, 2010.

R. Salem, R. J. Lewandowski, L. Kulik, E. Wang, A. Riaz et al., Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology. févr, vol.140, issue.2, pp.497-507, 2011.

A. Gramenzi, R. Golfieri, C. Mosconi, A. Cappelli, A. Granito et al., Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis, Liver Int Off J Int Assoc Study Liver. mars, vol.35, issue.3, pp.1036-1083, 2015.

M. Iñarrairaegui, K. G. Thurston, J. I. Bilbao, D. 'avola, D. Rodriguez et al., Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis, J Vasc Interv Radiol JVIR. août, vol.21, issue.8, pp.1205-1217, 2010.

R. Salem, R. Lewandowski, C. Roberts, J. Goin, K. Thurston et al., Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis, J Vasc Interv Radiol JVIR. avr, vol.15, issue.4, pp.335-380, 2004.

L. M. Kulik, B. I. Carr, M. F. Mulcahy, R. J. Lewandowski, B. Atassi et al., Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatol Baltim Md. janv, vol.47, issue.1, pp.71-81, 2008.

M. Vouche, A. Habib, T. J. Ward, E. Kim, L. Kulik et al., Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiologypathology correlation and survival of radiation segmentectomy: VOUCHE ET AL, Hepatology. juill, vol.60, issue.1, pp.192-201, 2014.

R. J. Lewandowski, L. M. Kulik, A. Riaz, S. Senthilnathan, M. F. Mulcahy et al., A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. août, vol.9, issue.8, pp.1920-1928, 2009.

S. Tohme, D. Sukato, H. Chen, N. Amesur, A. B. Zajko et al., Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience, J Vasc Interv Radiol JVIR. nov, vol.24, issue.11, pp.1632-1640, 2013.

A. Braat, J. E. Huijbregts, I. Q. Molenaar, I. Borel-rinkes, M. Van-den-bosch et al., Hepatic radioembolization as a bridge to liver surgery, Front Oncol, vol.4, p.199, 2014.

S. Vyas, S. Markar, S. Partelli, T. Fotheringham, D. Low et al., Portal Vein Embolization and Ligation for Extended Hepatectomy, Indian J Surg Oncol. mars, vol.5, issue.1, pp.30-42, 2014.

N. Chauhan, J. Bukovcan, E. Boucher, D. Cosgrove, E. J. Hamilton et al., Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial, JMIR Res Protoc. 15 août, vol.7, issue.8, p.11234, 2018.

M. Bouattour, E. Assenat, B. Guiu, D. Ilonca-alina, G. Pageaux et al., Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial, Ann Oncol, vol.1, issue.2017

,

P. Chow, M. Gandhi, S. Tan, M. W. Khin, A. Khasbazar et al., Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.36, issue.19, pp.1913-1934, 2018.

V. Gebski, E. Gibbs, M. Gandhi, G. Chatellier, A. Dinut et al., VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials, JMIR Res Protoc. 15 févr, vol.6, issue.2, p.17, 2017.

. Btg and . Oncologye--target,

, Collège National des Enseignants en Cancérologie. Cancérologie. MED-LINE, 2017.

S. Sfro, Thésaurus National de Cancérologie Digestive -Cancer des voies biliaires, 2014.

G. Marret, C. Neuzillet, B. Rousseau, and C. Tournigand, Traitements médicaux des cholangiocarcinomes en, Bull Cancer (Paris). avr, vol.103, issue.4, pp.389-99, 2015.

D. P. Al-adra, R. S. Gill, S. J. Axford, X. Shi, N. Kneteman et al., Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis, Eur J Surg Oncol EJSO. janv, vol.41, issue.1, pp.120-127, 2015.

. Sirtex, Les nouvelles directives de la Société Éuropéenne d'Oncologie Médicale (ÉSMO) en matière de cancer des voies biliaires indiquent une radiothérapie interne sélective (SIRT) avec des microsphères marquées à l'Yttrium 90 comme option pour le traitement postchimiothérapie d'un cholangiocarcinome intra-hépatique (CCI), 2016.

H. Bourien, X. Palard, Y. Rolland, L. Du, F. Beuzit et al., Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience, Eur J Nucl Med Mol Imaging, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01937263

J. Edeline, Y. Touchefeu, B. Guiu, O. Farges, D. Tougeron et al., Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in firstline treatment of advanced cholangiocarcinoma (MISPHEC study), Ann Oncol, 2017.

A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA Cancer J Clin. avr, vol.61, issue.2, pp.69-90, 2011.

R. J. Lewandowski, K. Memon, M. F. Mulcahy, R. Hickey, K. Marshall et al., Twelveyear experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy, Eur J Nucl Med Mol Imaging, vol.41, issue.10, pp.1861-1870, 2014.

S. Manfredi, A. M. Bouvier, C. Lepage, C. Hatem, V. Dancourt et al., Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population, Br J Surg. sept, vol.93, issue.9, pp.1115-1137, 2006.

B. Nordlinger, H. Sorbye, B. Glimelius, G. J. Poston, P. M. Schlag et al., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, Lancet Lond Engl. 22 mars, vol.371, issue.9617, pp.1007-1023, 2008.

F. , Thésaurus National de Cancérologie Digestive -Cancer colorectal métastatique, 2018.

M. Xing, D. A. Kooby, B. F. El-rayes, N. Kokabi, J. C. Camacho et al., Locoregional therapies for metastatic colorectal carcinoma to the liver-An evidence-based review: Locoregional Therapies for CRLM, J Surg Oncol. août, vol.110, issue.2, pp.182-96, 2014.

E. Van-cutsem, A. Cervantes, B. Nordlinger, D. Arnold, . Esmo-guidelines-working et al., Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.25, issue.3, pp.1-9, 2014.

S. Welch, K. Spithoff, R. B. Rumble, and J. Maroun, Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review, Ann Oncol Off J Eur Soc Med Oncol. juin, vol.21, issue.6, pp.1152-62, 2010.

V. Lemmens, N. De-haan, H. Rutten, H. Martijn, O. Loosveld et al., Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, Clin Exp Metastasis. mars, vol.28, issue.3, pp.283-90, 1992.

H. J. Meulenbeld, L. N. Van-steenbergen, M. Janssen-heijnen, V. Lemmens, and G. J. Creemers, Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.19, issue.9, pp.1600-1604, 1990.

A. Saxena, L. Bester, L. Shan, M. Perera, P. Gibbs et al., A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases, J Cancer Res Clin Oncol. avr, vol.140, issue.4, pp.537-584, 2014.

A. Hendlisz, M. Van-den-eynde, M. Peeters, G. Maleux, B. Lambert et al., Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy, J Clin Oncol Off J Am Soc Clin Oncol. 10 août, vol.28, issue.23, pp.3687-94, 2010.

H. S. Wasan, P. Gibbs, N. K. Sharma, J. Taieb, V. Heinemann et al., First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials, Lancet Oncol, vol.18, issue.9, pp.1159-71, 2017.

, TheraSphere Trials. EPOCH Clinical -Trial Information, p.89

S. Sfro, Thésaurus National de Cancérologie Digestive -Tumeurs neurendocrines digestives, 2015.

C. Lepage, Épidémiologie des tumeurs neuroendocrines intestinales. Côlon Rectum, vol.11, pp.207-218, 2017.

J. Scoazec, Classification et facteurs pronostiques des tumeurs neuroendocrines intestinales. Côlon Rectum, vol.11, pp.212-221, 2017.

A. S. Kennedy, W. A. Dezarn, P. Mcneillie, D. Coldwell, C. Nutting et al., Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients, Am J Clin Oncol. juin, vol.31, issue.3, pp.271-280, 2008.

Z. Jia, R. Paz-fumagalli, G. Frey, D. M. Sella, J. M. Mckinney et al., Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors: Y-90 treat liver neuroendocrine tumor, J Gastroenterol Hepatol. sept, vol.32, issue.9, pp.1617-1640, 2017.

Z. Jia and W. Wang, Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review, Eur J Radiol. mars, vol.100, pp.23-32, 2018.

H. Cnedimts, Avis de la CNEDiMTS du 24 mars, 2015.

. Légifrance, Arrêté du 14 février 2017 portant inscription de SIR-SPHERES de la société SIRTEX MEDICAL EUROPE GmbH au titre III de la liste des produits

H. Cnedimts, Avis de la CNEDiMTS du 6 novembre, 2018.

. Légifrance, Arrêté du 21 décembre 2018 portant inscription de THERASPHERE de la société BTG au titre III de la liste des produits

H. Cnedimts, Avis de la CNEDiMTS du 20 février, 2018.

A. Kennedy, S. Nag, R. Salem, R. Murthy, A. J. Mcewan et al., Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium, Int J Radiat Oncol. mai, vol.68, issue.1, pp.13-23, 2007.

E. Garin, Y. Rolland, E. J. Icard, N. Lenoir, L. Laffont et al., Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis, J Nucl Med. 1 mars, vol.56, issue.3, pp.339-385, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01128116

S. Tohme, D. Sukato, G. W. Nace, A. Zajko, N. Amesur et al., Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer, HPB. déc, vol.16, issue.12, pp.1110-1116, 2014.

M. J. Powerski, C. Erxleben, C. Scheurig-münkler, D. Geisel, B. Hamm et al., Anatomic variants of arteries often coil-occluded prior to hepatic radioembolization, Acta Radiol Stockh Swed, vol.56, issue.2, pp.159-65, 1987.

Y. Rolland, Radioembolisation à l'Yttrium-90 : le coiling des branches extra hépatiques est-il nécessaire ?, 2013.

R. De-gersem, G. Maleux, H. Vanbilloen, K. Baete, C. Verslype et al., Influence of Time Delay on the Estimated Lung Shunt Fraction on 99mTc-Labeled MAA Scintigraphy for 90Y Microsphere Treatment Planning, Clin Nucl Med. nov, vol.1, 2013.

C. L. Wright, J. D. Werner, J. M. Tran, V. L. Gates, A. A. Rikabi et al., Radiation Pneumonitis Following Yttrium-90 Radioembolization: Case Report and Literature Review, J Vasc Interv Radiol. mai, vol.23, issue.5, pp.669-74, 2012.

S. A. Gulec, G. Mesoloras, and M. Stabin, Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations, J Nucl Med Off Publ Soc Nucl Med. juill, vol.47, issue.7, pp.1209-1220, 2006.

N. Yu, S. M. Srinivas, F. P. Difilippo, S. Shrikanthan, A. Levitin et al., Lung Dose Calculation With SPECT/CT for 90Yittrium Radioembolization of Liver Cancer, Int J Radiat Oncol. mars, vol.85, issue.3, pp.834-843, 2013.

H. Ilhan, A. Goritschan, P. Paprottka, T. F. Jakobs, W. P. Fendler et al., Systematic Evaluation of Tumoral 99mTc-MAA Uptake Using SPECT and SPECT/CT in 502 Patients Before 90Y Radioembolization, J Nucl Med. 1 mars, vol.56, issue.3, pp.333-341, 2015.

M. Bernardini, C. Smadja, M. Faraggi, S. Orio, A. Petitguillaume et al., Liver Selective Internal Radiation Therapy with 90Y resin microspheres: Comparison between pretreatment activity calculation methods, Phys Med. nov, vol.30, issue.7, pp.752-64, 2014.

W. Lau, A. S. Kennedy, Y. H. Kim, H. K. Lai, R. Lee et al., Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres, Int J Radiat Oncol. janv, vol.82, issue.1, pp.401-408, 2012.

M. Lam, J. D. Louie, M. Abdelmaksoud, G. A. Fisher, C. D. Cho-phan et al., Limitations of Body Surface Area-Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer, J Vasc Interv Radiol. juill, vol.25, issue.7, pp.1085-93, 2014.

Y. H. Kao, H. Tan, A. E. Burgmans, M. C. Irani, F. G. Khoo et al., Image-Guided Personalized Predictive Dosimetry by Artery-Specific SPECT/CT Partition Modeling for Safe and Effective 90Y Radioembolization, J Nucl Med. 1 avr, vol.53, issue.4, pp.559-66, 2012.

R. Lhommel, P. Goffette, M. Van-den-eynde, J. F. Pauwels, S. Bilbao et al., Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT, Eur J Nucl Med Mol Imaging, vol.36, issue.10, pp.1696-1696, 2009.

A. Riaz, R. J. Lewandowski, L. M. Kulik, M. F. Mulcahy, K. T. Sato et al., Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review, J Vasc Interv Radiol. sept, vol.20, issue.9, pp.1121-1151, 2009.

R. Salem, R. J. Lewandowski, L. Kulik, E. Wang, A. Riaz et al., Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology. févr, vol.140, issue.2, pp.497-507, 2011.

R. Salem, R. J. Lewandowski, M. F. Mulcahy, A. Riaz, R. K. Ryu et al., Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology. janv, vol.138, issue.1, pp.52-64, 2010.

E. A. Wang, S. R. Broadwell, R. J. Bellavia, and J. P. Stein, Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma, J Gastrointest Oncol. avr, vol.8, issue.2, pp.266-78, 2017.

B. Sangro, B. Gil-alzugaray, J. Rodriguez, I. Sola, A. Martinez-cuesta et al., Liver disease induced by radioembolization of liver tumors: Description and possible risk factors, Cancer. 1 avr, vol.112, issue.7, pp.1538-1584, 2008.

B. Gil-alzugaray, A. Chopitea, M. Iñarrairaegui, J. I. Bilbao, M. Rodriguez-fraile et al., Prognostic factors and prevention of radioembolization-induced liver disease, Hepatol Baltim Md. mars, vol.57, issue.3, pp.1078-87, 2013.

E. Garin, L. Lenoir, Y. Rolland, S. Laffont, M. Pracht et al., Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres, Nucl Med Commun. déc, vol.32, issue.12, pp.1245-55, 2011.

E. Garin, L. Lenoir, Y. Rolland, E. J. Mesbah, H. Laffont et al., Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results, J Nucl Med. 1 févr, vol.53, issue.2, pp.255-63, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00866987

C. Chiesa, M. Mira, M. Maccauro, R. Romito, C. Spreafico et al., A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of. déc, vol.56, issue.6, pp.503-511, 2012.

L. Strigari, R. Sciuto, S. Rea, L. Carpanese, G. Pizzi et al., Efficacy and Toxicity Related to Treatment of Hepatocellular Carcinoma with 90Y-SIR Spheres: Radiobiologic Considerations, J Nucl Med. 1 sept, vol.51, issue.9, pp.1377-85, 2010.

S. Walrand, M. Hesse, C. Chiesa, R. Lhommel, and J. F. , The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging, J Nucl Med Off Publ Soc Nucl Med. janv, vol.55, issue.1, pp.135-175, 2014.

M. Smits, M. Elschot, D. Y. Sze, Y. H. Kao, J. Nijsen et al., Radioembolization Dosimetry: The Road Ahead, Cardiovasc Intervent Radiol. avr, vol.38, issue.2, pp.261-270, 2015.

, Predictive Value of 99mTc-Albumin Spheres Before 90Y-SIR Therapy (EXPLOSIVE)

E. Garin, Y. Rolland, E. Boucher, V. Ardisson, S. Laffont et al., First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation, Eur J Nucl Med Mol Imaging. mars, vol.37, issue.3, pp.453-61, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00742174

E. Garin, Y. Rolland, M. Pracht, L. Sourd, S. Laffont et al., High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization, Liver Int Off J Int Assoc Study Liver, vol.37, issue.1, pp.101-111, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01447063

Y. Kao, J. D. Steinberg, Y. Tay, G. K. Lim, J. Yan et al., Post-radioembolization yttrium-90 PET/CT -part 2: dose-response and tumor predictive dosimetry for resin microspheres, EJNMMI Res. 25 juill, vol.3, issue.1, p.57, 2013.

E. Garin, Y. Rolland, E. J. Icard, N. Lenoir, L. Laffont et al., Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis, J Nucl Med. 1 mars, vol.56, issue.3, pp.339-385, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01128116

C. Spreafico, C. Sposito, M. Vaiani, T. Cascella, S. Bhoori et al., Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion, J Hepatol. avr, vol.68, issue.4, pp.724-756, 2018.

K. Memon, L. M. Kulik, R. J. Lewandowski, E. Wang, J. Wang et al., Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization, J Vasc Interv Radiol JVIR. juill, vol.25, issue.7, pp.1056-66, 2014.

C. Chiesa, M. Mira, M. Maccauro, R. Romito, C. Spreafico et al., A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of. déc, vol.56, issue.6, pp.503-511, 2012.

W. Y. Lau, S. Ho, T. W. Leung, M. Chan, R. Ho et al., Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres, Int J Radiat Oncol Biol Phys. 1 févr, vol.40, issue.3, pp.583-92, 1998.

M. Jreige, P. Mitsakis, A. Van-der-gucht, A. Pomoni, M. Silva-monteiro et al., 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma, Eur J Nucl Med Mol Imaging. juill, vol.44, issue.7, pp.1215-1237, 2017.

. Serment-de-galien,

, Je jure, en présence des maîtres de la Faculté

, D'honorer ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement

, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur

, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine

, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser des actes criminels

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses

, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque